Table 3.
Biologic switch patterns among patient initiations
| Summary (N = 2580), n (%) | Time until switch (months), median (IQRa) | |
|---|---|---|
| Result of biologic initiation | ||
| Persistent at last visitb | 1973 (76.5) | – |
| Discontinuation without switchc | 103 (4.0) | – |
| Switch to different biologic | 504 (19.5) | 6.5 (4.6, 12.4) |
| MOA type after switchb | ||
| Switch to a biologic therapy within the same/initial MOA | 129 (25.6) | 8.0 (5.2, 16.4) |
| Switch to a biologic therapy with a different MOA | 375 (74.4) | 6.4 (4.5, 11.6) |
| Approval status of biologic therapiesd, e | ||
| Biologic approved for PsA → biologic approved for PsA | 248 (49.2) | 6.2 (4.4, 11.0) |
| Biologic approved for PsA → biologic not approved for PsA | 115 (22.8) | 6.4 (4.6, 11.8) |
| Biologic not approved for PsA → biologic approved for PsA | 77 (15.3) | 6.3 (4.8, 11.3) |
| Biologic not approved for PsA → biologic not approved for PsA | 64 (12.7) | 14.6 (8.1, 20.4) |
FDA Food and Drug Administration, IQR interquartile range, MOA mechanism of action, PsA psoriatic arthritis
aIQRs are presented as the first and third quartiles
bIndicates persistent use of the initial biologic therapy without switching at the last registry visit (non-switch)
cPatient stopped biologic therapy without switching to a new biologic (non-switch)
dAmong all patients that switched
eA biologic therapy was considered approved for PsA based on the FDA or Health Canada approval status at the time of initiation or switch